Rozanc J
ORCID: 0000-0003-4283-6087
· 1 paper in corpus
lab-animal
2019
Development of novel bioactive compounds against KRAS and/or BRAF mutant colorectal cancer (CRC) is currently an urgent need in oncology. In addition, single or multitarget kinase inhibitors against MEK/ERK and PI3K/AKT pathways are of pote…